RxDoctor Payments Data

Usha Agarwal, MD

Internal Medicine · Trinity, FLNPI 1427043421

Payments from drug & device makers

$2,311in general payments, 2019–2025

Across 117 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$305
  • GSK$218
  • Johnson & Johnson$192
  • Novo Nordisk$177
  • AstraZeneca$166
  • Merck$159
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$2,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,311 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$16,681
Medicare patients
61
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate159$156,851
BiktarvyBictegrav/Emtricit/Tenofov Ala40$156,350
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$39,092
JardianceEmpagliflozin23$32,061
EliquisApixaban31$31,820
FarxigaDapagliflozin Propanediol23$28,215
XareltoRivaroxaban21$20,723
OzempicSemaglutide16$14,838
Breo ElliptaFluticasone/Vilanterol28$14,680
MounjaroTirzepatide13$13,055
EntrestoSacubitril/Valsartan18$10,746
SymbicortBudesonide/Formoterol Fumarate24$7,811
Dabigatran EtexilateDabigatran Etexilate Mesylate34$7,614
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$7,456
Repatha SyringeEvolocumab11$6,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$159$156,851159 claims
GileadBiktarvy$146$156,35040 claims
GSKTrelegy Ellipta, Breo Ellipta$218$53,77270 claims
AstraZenecaFarxiga, Symbicort$166$36,02547 claims
Boehringer IngelheimJardiance$98$32,06123 claims
PfizerEliquis$150$31,82031 claims
Johnson & JohnsonXarelto$192$20,72321 claims
Novo NordiskOzempic$177$14,83816 claims
NovartisEntresto$148$10,74618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →